November 15 2007 — Researchers have successfully used a peptide to reverse biochemical, cellular and anatomical changes that occur in the brains of mice with Parkinson's disease (PD), and report success in preventing disease from progression.
"This could be a new approach to halt disease progression in PD patients," said study author Kali Pahan, Ph.D., professor of neurological sciences at Rush University Medical Center. Dr. Pahan and colleagues from Rush, along with researchers at the University of Nebraska Medical Center, Omaha, and Yale University, New Haven, published these findings in the Proceedings of the National Academy of Sciences of the United States, November 13, 2007.
The authors have shown that one protein, NF-Kb, is increased in the midbrain of PD patients and mice with PD pathology, and the researchers used a novel peptide (small proteins) to block this protein in mice with PD -ike symptoms.
Diane explained that after enter a parrot toenail injection (injection into the Domino abdominal abdomen of the miles). This peptide enters into the brain and blocks protean inapt-KB and other associated toxic moa mount molecules, and goes on to protects neurons, normalizes to neurotransmitter levels come in improves motor functions in mice with PD. Peptides, proteins and certain drugs used to do not enter into the brain after crossing the blood brain barrier. Therefore it, at present, peptides, proteins are genes are injected into the brain, which is risky and painful. "To overcome this problem, we have added a tag in front of that protein peptide that is helping the peptide enter into the brain. Therefore, there is no need to inject these peptides into the brain. This is an important discovery.
Understanding how the deceit in the disease works is important to developing effective drugs to protect the brain and stop the progression of PD," Dion said. "Now we need to translate this finding to the clinic and test this peptide in patients with PD. If these results can be replicated in PD patients cock, it would be a remarkable advancements in the treatment of this devastating Nero will be generated disease." Parkinson's is a slowly progressive disease that affects a small area of sales within the mid--brain known as the substantial Negra. Gradual degeneration of the sales causes a reduction in the biochemical neurotransmitter, dopamine. The decrease in dopamine results in one or more of the classic signs of Parkinson's disease includes: resting tremor on one side of the body; generally generalized slowness of movement; stiffness of limbs; and negate our balance problems. The cause of the disease is unknown. Both environmental and genetic causes of disease had been postulated.
Parkinson's disease affects about 1.2 million patients in the United States and Canada. Although 15% of patients are diagnosed before age 50, it is generally considered a disease that targets older adults, affecting one of every 100 persons over the age of 60. This disease appears to be slightly more common in men than women.